Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "LTI"

3160 News Found

FDA grants priority review to Tzield for youngest Type 1 diabetes patients
Drug Approval | January 07, 2026

FDA grants priority review to Tzield for youngest Type 1 diabetes patients

Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D


WuXi Biologics secures ISO 20400 certification
Sustainability | January 07, 2026

WuXi Biologics secures ISO 20400 certification

WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management


Merck completes acquisition of Cidara Therapeutics
News | January 07, 2026

Merck completes acquisition of Cidara Therapeutics

Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market


Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Opinion | January 07, 2026

Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader

India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry


Jubilant Ingrevia appoints Pravesh Kumar Garg as Chief of Manufacturing
People | January 06, 2026

Jubilant Ingrevia appoints Pravesh Kumar Garg as Chief of Manufacturing

Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence


Thyrocare appoints Rajdeep Panwar as Chief Commercial Officer
People | January 06, 2026

Thyrocare appoints Rajdeep Panwar as Chief Commercial Officer

Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector


RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects
Clinical Trials | January 06, 2026

RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects

The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation


PathoCare Holdings valued at $1.75 billion following major third-party tender offer
News | January 06, 2026

PathoCare Holdings valued at $1.75 billion following major third-party tender offer

The company previously completed a $150 million venture investment, acquisition, and recapitalization


Nia Therapeutics unveils first implantable brain interface for memory disorders
News | January 06, 2026

Nia Therapeutics unveils first implantable brain interface for memory disorders

The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices


Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
R&D | January 06, 2026

Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs

Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments